Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Beneficial Ownership Report · SCHEDULE 13G

BioStem Technologies, Inc.

BSEMNASDAQEQUITYCurrent

Beneficial Ownership Report

Filed Nov 10, 2026Accepted Nov 10, 2026, 4:15 PM ESTFiling CIK 1658678Accession 0001213900-26-118035
Share

Structured filing — SCHEDULE 13G

primary_doc.xml

Open full document ↗

Subject company

Company
BioStem Technologies, Inc.
Company CIK
0001658678
Street
2836 Center Port Circle
City
Pompano Beach
State / country code
FL
Postal code
33064

Statement details

Security class
Common Stock, $0.001 par value (the "Common Stock")
Event date
09/30/2026
Rule designation
Rule 13d-1(d)

Reporting person 1

Name
Jason Matuszewski
Citizenship / organization
X1
Reporting person type
IN
Aggregate amount owned
3,665,899.00
Percent of class
17.4
Sole voting power
3,665,899.00
Shared voting power
0.00
Sole dispositive power
3,665,899.00
Shared dispositive power
0.00
Aggregate excludes certain shares
N
Comments
(1) Based on 18,672,125 shares of Common Stock outstanding as of October 1, 2026, as reported in the Issuer's Registration Statement on Form S-1 filed on October 2, 2026, plus 2,362,348 shares issuable to the Reporting Person upon exercise or conversion of derivative securities exercisable within 60 days of September 30, 2026, computed in accordance with Rule 13d-3(d)(1)(i).

Item 1

Issuer

BioStem Technologies, Inc.

Principal executive office address

2836 Center Port Circle, Pompano Beach, Florida 33064

Item 2

Citizenship

United States.

Filing person

Jason Matuszewski (the "Reporting Person").

Principal business or residence address

c/o BioStem Technologies, Inc., 2836 Center Port Circle, Pompano Beach, Florida 33064.

Item 3

Not applicable indication

Y

Item 4

Percent of class

17.4%. See footnote (1) to the cover page.

Amount beneficially owned

3,665,899 shares of Common Stock, consisting of: (i) 1,303,551 shares of Common Stock held directly; (ii) 2,250,000 shares of Common Stock issuable upon exercise of fully vested options with an exercise price of $2.00 per share expiring October 24, 2032; (iii) 98,907 shares of Common Stock issuable upon exercise of the vested portion of options to purchase 198,807 shares at $10.05 per share expiring March 17, 2035; (iv) 13,341 shares of Common Stock issuable upon exercise of the portion of options to purchase 40,427 shares at $10.05 per share expiring October 13, 2035 that vests on October 13, 2026; and (v) 100 shares of Common Stock issuable upon conversion of 100 Series A-1 Convertible Preferred Shares. The amount excludes restricted stock units covering an aggregate of 497,411 shares not scheduled to vest on or before November 29, 2026. The amount also excludes options to purchase 440,529 shares at $5.50 per share not scheduled to vest on or before November 29, 2026.

Sole voting power

3,665,899

Shared voting power

0

Sole dispositive power

3,665,899

Shared dispositive power

0

Item 5

Not applicable indication

Y

Item 6

Not applicable indication

Y

Item 7

Not applicable indication

Y

Item 8

Not applicable indication

Y

Item 9

Not applicable indication

Y

Item 10

Not applicable indication

Y

Signature 1

Reporting person
Jason Matuszewski
Signed
/s/ Jason Matuszewski
Title
Jason Matuszewski
Date
11/10/2026

Company context

BioStem Technologies, Inc. is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain®, CryoTek® and SteriTek® processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine.

Current securities

Historical securities (5)

Recent company filings

  1. 4 filingNov 19, 2026
  2. 424B3 filingNov 19, 2026
  3. 424B3 filingNov 19, 2026
  4. 424B3 filingNov 19, 2026
  5. 10-Q filingNov 12, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.